Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study
Acta Obstetricia et Gynecologica Scandinavica · 2026
DOI: 10.1111/aogs.70319 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2026. Verfasst von Jiao Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Center, National Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Tradition…. Hauptthemen laut MEDLINE: Pre-Eclampsia, Pregnancy Trimester, First, Placenta Growth Factor, Prenatal Diagnosis. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The first‐trimester combined screening test for preterm preeclampsia (preterm‐PE) has been implemented in Mainland China. This study aims, first, to evaluate the applicability of multiple of the median (MoM) models based on biomarkers developed and utilized in a European population for prospective preterm‐PE screening in Mainland China; second, to assess the criteria for biomarker adjustment; and third, to establish criteria for continuous quality assurance in the screening process. Material and Methods In this prospective multicenter cross‐sectional study, 22 066 singleton pregnancies undergoing preterm‐PE screening at 11 + 0 –13 + 6 weeks were recruited from six tertiary hospitals in Mainland China. Mean arterial pressure (MAP) and placental growth factor (PlGF) were measured and converted to their equivalent MoM values using Fetal Medicine Foundation MoMing models incorporated in commercial software. PlGF levels were also determined using immunoassays developed in China. MoM and log 10 MoM distributions in the initial screened subjects were assessed for (1) central tendency and dispersion and (2) whether biomarker MoM distributions needed to be recentered. Biomarker central tendency and temporal stability both before and after recentering were assessed using Cumulative Sum plots. Distribution central tendency was considered good if its median MoM was between 0.95 and 1.05 and acceptable if between 1.05 and 1.10.
Results
After excluding the initial 400 pregnancies from each center, all PlGF, but not all MAP MoM distributions, required recentering. Post‐recentering, the overall distribution median (95% confidence interval) MoM values for MAP and PlGF were 1.003 (1.001, 1.004) and 1.004 (0.996, 1.013), respectively.
Conclusions
Chinese centers performing combined PE screening should assess biomarker MoM distributions in their initial cases to ensure that they conform to the expected central tendencies assumed in the risk estimation models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Reproductive Center, National Clinical Research Center for Chinese Medicine, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Department of Obstetrics, Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China.
- Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, China.
- Department of Obstetrics and Gynaecology and Reproductive Medicine, Peking University First Hospital, Beijing, China.
- Department of Obstetrics, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Ton…
ORCID-Profile: Jiao Liu, Xiaotian Li, Qiongjie Zhou, Wang Xueyin, Chi Chiu Wang, Liona C Poon
Zitieren
APA
Liu, J., Li, X., Yang, H., Zhou, Q., Ying, H., Zhou, R., Zhang, Y., Xueyin, W., Xie, H., Tu, X., Kong, L., Qin, J., Wang, C. C., Lu, X., Nguyen-Hoang, L., Sahota, D. S., & Poon, L. C. (2026). Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70319
Vancouver
Liu J, Li X, Yang H, Zhou Q, Ying H, Zhou R, et al. Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70319
BibTeX
@article{Liu2026,
author = {Liu, Jiao and Li, Xiaotian and Yang, Huixia and Zhou, Qiongjie and Ying, Hao and Zhou, Rong and Zhang, Yanping and Xueyin, Wang and Xie, Han and Tu, Xinzhi and Kong, Lin and Qin, Jie and Wang, Chi Chiu and Lu, Xiaohong and Nguyen-Hoang, Long and Sahota, Daljit S and Poon, Liona C},
title = {Assessing quality standards of biomarker measurement in first‐trimester combined screening for preeclampsia in the Chinese population: A multicenter study},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
doi = {10.1111/aogs.70319}
}
EUVIMED